EXT2
Exostosin-2
Protein Summary
Glycosyltransferase required for the biosynthesis of heparan-sulfate. The EXT1/EXT2 complex possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone. Appears to be a tumor suppressor. Required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413). This gene encodes one of two glycosyltransferases involved in the chain elongation step of heparan sulfate biosynthesis. Mutations in this gene cause the type II form of multiple exostoses. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jul 2008]
- ENST00000343631
- ENSP00000342656
- ENSG00000151348
- ENST00000358681
- ENSP00000351509
- ENST00000395673
- ENSP00000379032
- ENST00000533608
- ENSP00000431173
- SOTV
- SSMS
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase perturbation | 0.99 | ||
disease perturbation | 0.83 | ||
cellular component | 0.8 | ||
virus perturbation | 0.76 | ||
transcription factor binding site profile | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 259.31 (req: < 5)
Gene RIFs: 78 (req: <= 3)
Antibodies: 218 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 259.31 (req: >= 5)
Gene RIFs: 78 (req: > 3)
Antibodies: 218 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 16
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0